Cuộc họp công bố kết quả kinh doanh quý 3/2026 của Veracyte (VCYT): Điều chỉnh triển vọng Decipher, tăng trưởng năm 2027 chậm lại
Doanh thu quý 3/2026 của Veracyte tăng 15% lên 151,8 triệu USD, nhưng công ty đã điều chỉnh lại kỳ vọng tăng trưởng của Decipher và dự báo mức tăng trưởng doanh thu ở mức một chữ số tầm trung cho năm 2027.
Veracyte, Inc. is a global diagnostics company. The Company enables clinicians with insights they need to guide and help patients to diagnose and treat cancer. The Veracyte Diagnostics Platform delivers cancer tests that are fueled by broad genomic and clinical data, deep bioinformatic and AI capabilities, and an evidence-generation engine, which drives durable reimbursement and guideline inclusion for its tests, along with new insights to support continued innovation and pipeline development. The Company offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna) and bladder cancer (Decipher Bladder). It has developed the noninvasive Percepta Nasal Swab test to help physicians accurately and quickly determine lung cancer risk. All of its tests are serviced through its own Clinical Laboratory Improvement Amendments (CLIA) certified laboratories in South San Francisco, California, San Diego, California and Austin, Texas.